Financials data is unavailable for this security.
View more
Year on year PRISM BioLab Co Ltd 's revenues fell -79.63% from 554.40m to 112.93m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 72.96m to a loss of 526.91m.
Gross margin | -- |
---|---|
Net profit margin | -- |
Operating margin | -- |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at PRISM BioLab Co Ltd fell by 554.05m. Cash Flow from Investing was negative at 40.38m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 513.81m for operations while cash used for financing totalled .
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 66.29 |
---|---|
Tangible book value per share | 66.29 |
More ▼
Balance sheet in JPYView more
Current ratio | 2.81 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼
Growth rates in JPY
Year on year, growth in earnings per share excluding extraordinary items dropped -822.18%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -- |